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Background: Obesity is a major global epidemic and a burden to society and health systems. It is well known risk
factor for a number of chronic medical conditions with high morbidity and mortality. This study aimed to provide
an estimate of the direct costs associated to outpatient and inpatient care of overweight and obesity related
diseases in the perspective of the Brazilian Health System (SUS).
Methods: Population attributable risk (PAR) was calculated for selected diseases related to overweight and obesity
and with the following parameters: Relative risk (RR)≥ 1.20 or RR ≥1.10 and< 1.20, but important problem of public
health due its high prevalence. After a broad search in the literature, two meta-analysis were selected to provide RR
for PAR calculation. The prevalence rates of overweight and obesity in Brazilians with ≥18 years were obtained from
large national survey. The national health database (DATASUS) was used to estimate the annual cost of the Brazilian
Unified Health System (SUS) with the diseases included in the analysis. The extracted values were stratified by sex,
type of service (inpatient or outpatient care) and year. Data were collected from 2008 to 2010 and the results reflect
the average of 3 years. Brazilian costs were converted into US dollars during the analysis using a purchasing power
parity basis (2010).
Results: The estimated total costs in one year with all diseases related to overweight and obesity are US$ 2,1
billion; US$ 1,4 billion (68.4% of total costs) due to hospitalizations and US$ 679 million due to ambulatory
procedures. Approximately 10% of these cost is attributable to overweight and obesity.
Conclusion: The results confirm that overweight and obesity carry a great economic burden for Brazilian health
system and for the society. The knowledge of these costs will be useful for future economic analysis of preventive
and treatment interventions.
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Over the past several decades, obesity has grown into a
major global epidemic. World Health Organization
(WHO) estimated that globally in 2005, approximately
1.6 billion adults were overweight and at least 400 mil-
lion adults were obese. They also predicted that by 2015,
approximately 2.3 billion adults would be overweight* Correspondence: lucianabahia@gmail.com
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reproduction in any medium, provided the orand more than 700 million would be obese [1]. In Brazil,
two national surveys of adult population showed that
overweight and obesity prevalence rates has increased
over the past 4 years, from 43% to 48.1% and from 11%
to 15% for overweight and obesity respectively [2,3].
Overweight and obesity are known risk factors for a
number of chronic medical conditions, like cancer, dia-
betes, or heart disease, that in turn are primary drivers of
health care spending, disability, and death. The estimated
numbers of obesity-attributed cancers are large and in-
clude common cancer as pancreas, colorectum, breast,
and endometrium. In the United States the impact oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Relative risks and respective 95% confidence
intervals, by gender, for selected diseases
Disease Overweight Obesity
Colon-rectum cancer M: 1.48 (1.23-1.79) M: 1.95 (1.51-2.51)
W: 1.55 (1.30-1.86) W: 1.49 (1.21-1.82)
Ovary cancer W: 1.29 (1.12-1.23) W :1.47 (1.13-1.91)
Endometrium cancer W: 1.90 (1.53-2.36) W: 3.39 (2.51-4.58)
Diabetes II M: 2.29 (1.98-2.64) M: 5.36 (4.32-6.65)
W: 3.64 (2.93-4.52) W: 10.47 (7.31-15.0)
Arterial hypertension M: 2.34 (1.85-2.98) M :5.93 (4.39-8.0)
W: 2.04 (1.33-3.12) W: 3.48 (2.12-5.71)
Stroke M: 1.23 (1.13-1.34) M: 1.51 (1.33-1.72)
W: 1.15 (1.00-1.32) W: 1.49 (1.27-1.74)
Ischemic Heart Disease M: 1.29 (1.18-1.41) M: 1.72 (1.51-1.96)
W: 1.14 (0.88-1.48) W: 1.91 (1.45-2.50)
Congestive Heart Failure (men) M: 1.36 (1.01-1.83) M: 1.80 (1.27-2.56)
W: not included W: 1.78 (1.07-2.95)
Asthma M: 1.20 (1.08-1.33) M: 1.43 (1.14-1.79)
W: 1.25 (1.05-1.49) W: 1.78 (1.36-2.32)
Osteoarthritis (knee and hip) M: 2.01 (1.92-2.09) M: 2.47 (2.27-2.70)
W: 1.80 (1.75-1.85) W: 1.96 (1.88-2.04)
Pancreas cancer M: not included M: 2.74 (1.60-4.67)
W: not included W: 1.57 (1.06-2.33)
Kidney cancer M: not included M: 1.97 (1.20-3.22)
W: not included W: 1.99 (1.42-2.78)
Gallbladder cancer M: 1.15 (1.01-1.30) M: 1.35 (1.09-1.68)
W: 1.15 (1.01-1.30) W: 1.88 (1.66-2.13)
Post-menopausal
breast cancer
W: 1.11 (1.01-1.22) W: 1.17 (1.04-1.32)
M:men; W:women.
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for about 6% of all cancers in that country [4]. A study
reported that obesity-related morbidity is greater than that
associated with smoking, drinking, or poverty in the Uni-
ted States [5].
The economic costs of obesity have raised consider-
able attention in recent years. The cost, or burden, of an
illness can be measured by the financial impact of
related diseases on the health system (direct costs) and
by the loss of productivity and quality of life (indirect
costs) to society and individuals. Obesity presents a
major health challenge, especially in developing coun-
tries as Brazil and the costs are substantial, although un-
known in most health systems.
The primary objective of this study is to provide an es-
timate of the direct costs associated to outpatient and
inpatient care of overweight and obesity-related diseases
in the perspective of the Brazilian Health System (SUS).
Methods
Population attributable risk
Population attributable risk (PAR) is the proportion of
the incidence of a disease in the population that is due
to exposure to a particular risk factor. It is the incidence
of a disease in the population that would be eliminated
if exposure were suppressed. This section describes the
procedures for the selection of diseases and to estimate
the PAR used for the cost study.
Two groups of exposure were of interest for estimating
the PAR: individuals with overweight (body mass index-
BMI 25-29.9 Kg/m2) and obesity (BMI≥ 30 Kg/m2).
The related diseases were selected for calculating PAR
if their associations with overweight and obesity have
the following parameters: Relative risk (RR) ≥ 1.20 or
Relative risk (RR) ≥1.10 and< 1.20, but important prob-
lem of public health due its high prevalence.
The estimate of PAR was done by Levin’s formula,
defined as the proportion of all cases that would not
have occurred if the exposure had been absent [6].
PAR ¼ Pe RR  1ð Þ
Pe RR 1ð Þ þ 1
where Pe is the prevalence of exposure and RR the rela-
tive risk.
Sources of relative risks estimates
First, we searched for meta-analyses presenting RR esti-
mates associated to the presence of overweight and obesity.
After identifying the most recent meta-analyses, we looked
for large individual studies published after the search period
covered by the meta-analyses. We conducted a literature
search in two databases, Medline and Scopus. The search
always contained two blocks of concepts: one of thedescriptors of exposure (overweight or obesity) and the
other descriptors related to the selected outcomes. The
Table 1 presents the relative risks and respective 95% confi-
dence intervals, by gender, for the selected diseases (for
overweight and obesity).
The quality evaluation of the meta-analyses was done
by AMSTAR inventory, that scored the methodological
aspects of the meta-analyses used in this study [7]. The
meta-analyses done by Guh et al. [8] and Larson et al.
[9] were selected to provide RR for PAR calculation.Sources of population estimates for the exposures
The prevalence rates of overweight and obesity in indivi-
duals with ≥18 years were obtained from a recent and
large national survey called VIGITEL study [3], which
assessed by telephone interviews 54.339 individuals,
20.764 men and 33.575 women. This study made use of
self-reported data on weight and height to calculate the
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lence for overweight and obesity separately, stratified by
gender and state.
Cost estimates
DATASUS database was used to estimate the annual
cost of the Brazilian Unified Health System (SUS) with
diseases that were included in the analysis [10]. This
database provides the reimbursed values by the govern-
ment for public health care organizations that provide
health care (inpatient and outpatient) needed for treat-
ment and monitoring of these diseases. The values
extracted from DATASUS were stratified by sex, type of
service (inpatient or outpatient care) and year. Data were
collected from 2008 to 2010 and the results reflect the










M W M W W M W M W
Aracajú 14.14 14.53 21.76 3.29 8.22 4.89 4.43 6.42 7.17
Belém 14.87 12.89 19.49 2.87 7.24 5.18 3.88 6.79 6.30
Belo Horizonte 14.31 13.63 20.53 3.06 7.68 4.96 4.13 6.51 6.69
Boa Vista 13.89 12.68 19.20 2.82 7.11 4.80 3.81 6.30 6.19
Campo Grande 15.97 14.00 21.04 3.15 7.91 5.61 4.25 7.34 6.89 1
Cuiabá 14.42 13.43 20.24 3.01 7.56 5.00 4.06 6.56 6.59
Curitiba 15.43 12.09 18.37 2.68 6.76 5.39 3.61 7.06 5.88
Florianópolis 15.67 12.30 18.67 2.73 6.89 5.49 3.68 7.18 5.99 1
Fortaleza 13.42 16.41 24.32 3.78 9.38 4.62 5.08 6.07 8.19
Goiânia 16.17 12.26 18.61 2.72 6.86 5.69 3.67 7.44 5.97 1
João Pessoa 15.80 13.18 19.90 2.95 7.41 5.54 3.98 7.25 6.45 1
Macapá 15.87 12.34 18.73 2.74 6.91 5.57 3.70 7.29 6.02 1
Maceió 15.22 13.22 19.96 2.96 7.44 5.31 3.99 6.96 6.48
Manaus 14.91 12.93 19.55 2.88 7.26 5.19 3.89 6.80 6.32
Natal 14.14 14.28 21.43 3.23 8.08 4.89 4.35 6.42 7.04
Palmas 11.88 9.91 15.25 2.15 5.48 4.04 2.91 5.32 4.76
Porto Alegre 15.80 15.09 22.52 3.43 8.56 5.54 4.62 7.25 7.47 1
Porto Velho 16.31 13.05 19.72 2.92 7.34 5.74 3.93 7.51 6.39 1
Recife 14.31 14.20 21.32 3.20 8.03 4.96 4.32 6.51 7.00
Rio Branco 18.31 13.39 20.19 3.00 7.53 6.55 4.04 8.54 6.56 1
Rio de Janeiro 16.88 14.45 21.65 3.27 8.18 5.97 4.40 7.80 7.13 1
Salvador 13.35 12.72 19.26 2.83 7.14 4.59 3.82 6.03 6.21
São Luis 13.78 12.13 18.43 2.69 6.79 4.76 3.63 6.24 5.90
São Paulo 15.01 14.32 21.48 3.24 8.10 5.23 4.36 6.86 7.06
Teresina 15.77 10.22 15.70 2.23 5.66 5.53 3.01 7.24 4.92 1
Vitória 15.43 11.32 17.27 2.49 6.30 5.39 3.36 7.06 5.48
Distrito Federal 19.04 10.57 16.21 2.31 5.87 6.85 3.12 8.93 5.10 1
Population Attributable Risk: PAR; M: Men; W: Women; EC: Endometrial Cancer; PBC
Heart Disease.Brazil's capitals, the values were extracted from DATA-
SUS initially by capital and later by state.
Brazilian costs were converted into US dollars during
the analysis using a purchasing power parity basis (PPP
2010: US$ 1 =R$ 1.7) [11].Results
The influence of overweight and obesity on selected dis-
eases varies a lot, from 2% to breast cancer (overweight)
to 66.43% to type 2 diabetes mellitus (obesity). The cal-
culated overweight and obesity PAR are listed in Tables 2
and 3.
The estimated total costs in one year with all diseases
related to overweight and obesity are US$ 2,152,102,171.
Hospitalizations account to US$ 1,472,742,952, 68.4% ofpercentage, for the selected diseases
IHD Osteoarthritis Diabetes Hypertension Stroke CHF
M W M W M W M W M W M
9.05 4.15 25.73 19.82 30.67 44.93 31.49 24.32 7.31 4.43 10.99
9.55 3.63 26.88 17.71 31.95 41.53 32.78 21.86 7.73 3.88 11.59
9.17 3.86 26.01 18.67 30.98 43.11 31.80 22.99 7.41 4.13 11.13
8.88 3.56 25.34 17.44 30.24 41.07 31.05 21.54 7.17 3.81 10.79
0.30 3.98 28.57 19.15 33.81 43.87 34.67 23.54 8.35 4.25 12.48
9.24 3.80 26.17 18.41 31.17 42.68 31.99 22.68 7.47 4.06 11.22
9.93 3.38 27.74 16.67 32.89 39.76 33.74 20.63 8.04 3.61 12.03
0.09 3.45 28.10 16.94 33.30 40.23 34.15 20.96 8.17 3.68 12.23
8.56 4.76 24.60 22.22 29.41 48.52 30.21 27.08 6.92 5.08 10.42
0.44 3.43 28.88 16.89 34.15 40.14 35.01 20.90 8.46 3.67 12.64
0.18 3.72 28.31 18.09 33.53 42.15 34.38 22.30 8.25 3.98 12.34
0.23 3.46 28.41 17.00 33.64 40.33 34.50 21.03 8.29 3.70 12.39
9.78 3.73 27.42 18.14 32.54 42.24 33.38 22.37 7.92 3.99 11.87
9.57 3.64 26.94 17.76 32.01 41.62 32.85 21.92 7.74 3.89 11.61
9.05 4.07 25.73 19.51 30.67 44.44 31.49 23.96 7.31 4.35 10.99
7.53 2.72 22.11 13.79 26.60 34.55 27.35 17.22 6.07 2.91 9.19
0.18 4.33 28.31 20.53 33.53 46.03 34.38 25.15 8.25 4.62 12.34
0.53 3.68 29.08 17.93 34.37 41.88 35.23 22.11 8.54 3.93 12.75
9.17 4.04 26.01 19.41 30.98 44.28 31.80 23.84 7.41 4.32 11.13
1.93 3.79 32.05 18.35 37.59 42.59 38.49 22.61 9.70 4.04 14.39
0.93 4.12 29.93 19.72 35.30 44.77 36.18 24.20 8.87 4.40 13.22
8.52 3.58 24.48 17.49 29.28 41.16 30.08 21.61 6.88 3.82 10.36
8.81 3.39 25.17 16.72 30.05 39.85 30.85 20.70 7.11 3.63 10.70
9.64 4.08 27.10 19.56 32.19 44.52 33.03 24.02 7.80 4.36 11.70
0.16 2.82 28.26 14.21 33.47 35.34 34.32 17.71 8.23 3.01 12.31
9.93 3.15 27.74 15.65 32.89 37.98 33.74 19.44 8.04 3.36 12.03
2.44 2.92 33.11 14.68 38.73 36.21 39.64 18.27 10.13 3.12 14.99
: Postmenopausal Breast cancer; CHF: Congestive Heart Failure; IHD: Ischemic











Asthma IHD CHF Osteoarthritis Diabetes Hypertension Stroke
M W W W W M W M W M W M W M W M W M W M W M W M W
Aracajú 12.18 6.72 26.00 2.44 6.46 20.26 7.73 12.41 12.70 4.86 11.45 5.91 10.29 9.51 11.80 10.46 10.29 17.67 12.37 38.90 58.20 41.85 26.72 6.93 6.72
Belém 13.05 6.16 24.26 2.23 5.92 21.56 7.10 13.29 11.71 5.24 10.55 6.36 9.46 10.21 10.87 11.22 9.46 18.85 11.40 40.79 55.93 43.79 24.94 7.46 6.16
Belo Horizonte 10.39 6.33 24.80 2.29 6.09 17.51 7.29 10.58 12.02 4.10 10.83 4.98 9.72 8.07 11.16 8.89 9.72 15.21 11.70 34.72 56.65 37.56 25.50 5.86 6.33
Boa Vista 12.18 7.65 28.77 2.79 7.36 20.26 8.79 12.41 14.33 4.86 12.95 5.91 11.65 9.51 13.33 10.46 11.65 17.67 13.96 38.90 61.54 41.85 29.53 6.93 7.65
Campo Grande 12.18 8.35 30.77 3.07 8.04 20.26 9.59 12.41 15.55 4.86 14.07 5.91 12.67 9.51 14.48 10.46 12.67 17.67 15.15 38.90 63.79 41.85 31.57 6.93 8.35
Cuiabá 15.29 8.27 30.54 3.03 7.96 24.85 9.49 15.56 15.41 6.24 13.94 7.55 12.55 12.03 14.34 13.19 12.55 21.83 15.01 45.31 63.54 48.37 31.33 8.83 8.27
Curitiba 14.60 7.81 29.25 2.86 7.52 23.85 8.98 14.86 14.62 5.93 13.21 7.18 11.89 11.47 13.60 12.59 11.89 20.92 14.24 43.97 62.10 47.02 30.02 8.41 7.81
Florianópolis 12.84 6.16 24.26 2.23 5.92 21.24 7.10 13.07 11.71 5.15 10.55 6.25 9.46 10.04 10.87 11.03 9.46 18.56 11.40 40.33 55.93 43.32 24.94 7.33 6.16
Fortaleza 17.09 6.89 26.52 2.50 6.63 27.41 7.92 17.39 13.00 7.06 11.73 8.53 10.54 13.51 12.08 14.79 10.54 24.18 12.66 48.62 58.85 51.69 27.25 9.96 6.89
Goiânia 10.00 5.60 22.43 2.02 5.38 16.91 6.45 10.19 10.70 3.93 9.62 4.79 8.62 7.77 9.92 8.56 8.62 14.68 10.41 33.78 53.40 36.58 23.08 5.63 5.60
João Pessoa 12.18 8.15 30.20 2.99 7.84 20.26 9.35 12.41 15.20 4.86 13.74 5.91 12.37 9.51 14.14 10.46 12.37 17.67 14.80 38.90 63.15 41.85 30.98 6.93 8.15
Macapá 11.89 8.06 29.96 2.95 7.76 19.81 9.26 12.11 15.05 4.73 13.61 5.75 12.25 9.28 14.01 10.20 12.25 17.27 14.66 38.24 62.90 41.18 30.74 6.75 8.06
Maceió 11.59 5.95 23.57 2.15 5.72 19.36 6.85 11.81 11.32 4.61 10.19 5.60 9.14 9.04 10.51 9.94 9.14 16.86 11.02 37.57 54.99 40.49 24.24 6.58 5.95
Manaus 12.98 8.88 32.23 3.27 8.55 21.46 10.19 13.22 16.46 5.21 14.90 6.32 13.44 10.16 15.33 11.16 13.44 18.75 16.04 40.64 65.33 43.63 33.04 7.41 8.88
Natal 13.27 7.77 29.13 2.84 7.48 21.88 8.93 13.51 14.55 5.33 13.15 6.47 11.83 10.39 13.53 11.41 11.83 19.14 14.17 41.24 61.96 44.25 29.90 7.59 7.77
Palmas 11.81 4.67 19.29 1.67 4.49 19.70 5.39 12.03 9.01 4.70 8.09 5.72 7.24 9.22 8.34 10.14 7.24 17.17 8.76 38.07 48.64 41.01 19.87 6.71 4.67
Porto Alegre 12.18 7.31 27.79 2.66 7.03 20.26 8.41 12.41 13.75 4.86 12.41 5.91 11.16 9.51 12.78 10.46 11.16 17.67 13.39 38.90 60.39 41.85 28.53 6.93 7.31
Porto Velho 11.96 9.29 33.31 3.43 8.94 19.92 10.64 12.18 17.14 4.77 15.53 5.79 14.02 9.33 15.98 10.27 14.02 17.37 16.71 38.40 66.43 41.35 34.14 6.80 9.29
Recife 16.10 6.85 26.39 2.49 6.59 26.01 7.88 16.38 12.93 6.60 11.66 7.99 10.47 12.70 12.01 13.91 10.47 22.90 12.59 46.83 58.69 49.90 27.11 9.34 6.85
Rio Branco 11.59 9.45 33.73 3.49 9.10 19.36 10.83 11.81 17.41 4.61 15.79 5.60 14.25 9.04 16.24 9.94 14.25 16.86 16.98 37.57 66.86 40.49 34.57 6.58 9.45
Rio de Janeiro 11.89 8.27 30.54 3.03 7.96 19.81 9.49 12.11 15.41 4.73 13.94 5.75 12.55 9.28 14.34 10.20 12.55 17.27 15.01 38.24 63.54 41.18 31.33 6.75 8.27
Salvador 7.06 6.38 24.94 2.31 6.13 12.22 7.34 7.20 12.10 2.72 10.90 3.33 9.78 5.45 11.23 6.02 9.78 10.52 11.77 25.86 56.83 28.28 25.64 3.92 6.38
São Luis 10.77 5.03 20.52 1.80 4.83 18.10 5.80 10.97 9.66 4.26 8.68 5.18 7.77 8.38 8.95 9.22 7.77 15.73 9.39 35.64 50.56 38.50 21.13 6.08 5.03
São Paulo 11.96 7.10 27.16 2.58 6.83 19.92 8.17 12.18 13.38 4.77 12.07 5.79 10.85 9.33 12.43 10.27 10.85 17.37 13.03 38.40 59.63 41.35 27.90 6.80 7.10
Teresina 12.40 5.86 23.29 2.11 5.63 20.59 6.75 12.63 11.17 4.96 10.05 6.02 9.01 9.69 10.36 10.65 9.01 17.97 10.87 39.38 54.60 42.35 23.95 7.06 5.86
Vitória 12.25 7.31 27.79 2.66 7.03 20.37 8.41 12.48 13.75 4.89 12.41 5.95 11.16 9.57 12.78 10.52 11.16 17.77 13.39 39.06 60.39 42.02 28.53 6.97 7.31
Distrito Federal 8.20 4.54 18.82 1.62 4.36 14.06 5.24 8.36 8.76 3.19 7.86 3.88 7.03 6.34 8.11 6.99 7.03 12.14 8.52 29.07 47.88 31.67 19.39 4.57 4.54
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http://www.biomedcentral.com/1471-2458/12/440total costs and ambulatory procedures account to US$
679,353,348 (Table 4).
Applying the PAR, overweight and obesity contribute
with percentages between 6.28% to 14.3% of these costs
according to sex, inpatient or outpatient care and pres-
ence of overweight or obesity.
Obesity attributable hospitalizations costs were higher
among men (US$ 47 million vs. US$ 46 million), al-
though PAR were lower than in women. The inverse
situation was seen regarding outpatient costs, with much
higher PAR but lower costs among men (US$ 12 million
vs. US$ 18 million).
The analysis stratified by groups of diseases showed
that the largest costs (out and inpatient care in both
sexes) were due to cardiovascular disease (US$ 747 mil-
lion) followed by overweight and obesity related neo-
plasms (US$ 299.8 million, mainly in women 79.5%),
asthma (US$ 34 million), diabetes mellitus (US$ 23.7
million) and osteoarthritis (US$ 3.9 million) (Table 5).
The major part of costs with cardiovascular diseases was
due to coronary artery disease (60.5%).
Discussion
The estimated costs of diseases related to overweight and
obesity reach almost US$ 2.1 billion in one year. Using
population attributable risk factor we could estimate that



















US$ 20,2 million (7.69%) US$ 2
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US$ 69,4 million (9.99%) US$ 3
milli




* Three years average (2008 to 2010) of costs related to selected diseases (Table 1).overweight and obesity. The estimates of direct costs
reviewed here may generally be conservative, probably
underestimated. The reimbursement rates provided by the
Brazilian healthcare system (SUS) are widely recognized
as poor estimates of the true costs of health care as shown
by some cost-of-illness studies in Brazil, showing much
higher costs than the reimbursed values [12,13]. If indirect
costs such as days lost to sickness, premature mortality,
out-of-pocket and home care expenses had been included,
the figure would have been far higher. Furthermore, this
study focused only on the cost of care provided at public
hospitals, the overall cost in Brazil will clearly be higher
than reported in this study if also private health care
spending had been included.
Costs for women were greater than for men, mainly be-
cause of higher ambulatory expenditures (73.3% vs 26.7% of
total costs for women and men, respectively). The preva-
lence rates for overweight and obesity in Brazil differed little
between sexes, and women demonstrated almost half of
PAR for selected diseases than men, suggesting a greater
use of health care system among them.
The largest proportion of costs was attributable to the
treatment of cardiovascular diseases (67%), most likely be-
cause of higher prevalence of coronary artery disease com-
pared to the selected neoplasms. In a previous study
carried out in Brazil, Sichieri et al. [14] also demonstrated





















































US$ 1 billion US$ 121,3 million
(11.59%)

















US$ 2,1 billion US$ 221 million
(10.27%)
Table 5 Annual costs separated by group of diseases
(women and men)




































































*Overweight and obesity related neoplasms **only as first diagnosis ***only
knee and hip.
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http://www.biomedcentral.com/1471-2458/12/440myocardial infarction and other ischemic heart diseases in
public health system in Brazil.
Cardiovascular diseases and diabetes mellitus, both very
common diseases with high morbidity and mortality rates,
are responsible for a significant number of hospitalizations
and high costs in Brazil [15,16]. Both conditions are
related to obesity and probably its prevalence and severity
could be reduced with the reduced obesity rates. Wang
et al. studied the economic burden of the projected obes-
ity trends in the United States of America (USA), and
demonstrated that a hypothetical program that enables a
1% BMI reduction across the US population would avoid
up to 2.1-2.4 million incident cases of diabetes, 1.4-1.7mil-
lion cardiovascular diseases, and 73,000-127,000 cases of
cancer [17].
The second group of diseases with the highest costs to
the public health system was neoplasms. With the trend
on increase prevalence of obesity along with the aging
population, the increase in cancer cases and costs involved
will be enormous.
Hospitalizations expenditures are often more important
and contributed to the majority of costs to health systems,
as presented in this analysis (approx 68% of total costs).
The total expenditures related to all hospital admissions in
Brazilian adult population (year 2010) amounted US$ 4.5
billion [18]. The estimate of obesity-related diseases expen-
ditures accounted for 32.9% of these costs, and approxi-
mately 11% of these costs can be attributable to overweight
and obesity. Likewise, Schieri et al. also studied the impact
of obesity on hospitalizations in Brazil, limiting the analysisto fewer diseases but including workdays lost due to
hospitalization. In their study overweight/obesity related
costs accounted for at least 3-5% of total hospitalization
costs in 2001 [14].
The estimated costs with obesity-related diseases are
equivalent to 0.09% of the Brazilian gross domestic prod-
uct in 2010 [19]. Similarly a recent review for Europe
which encompassed both direct and indirect costs esti-
mated obesity-related costs to range from 0.09% to 0.61%
of total annual gross domestic income in Western Euro-
pean countries [20]. In United Kingdom (UK), a review of
costs studies of overweight and obesity demonstrated that
both conditions were responsible for 7.3% of morbidity
and mortality in the UK, contributing over £3 billion to
the direct health cost burden to the public health system
(4.6% of total expenditure in 2002) [21]. In Korea total
costs represented about 0.22% of the gross domestic prod-
uct and 3.7% of the national health care expenditures in
2005 [22]. During the past 20 years, there has been a dra-
matic increase in obesity in the United States totalled and
in 2010, no state had a prevalence of obesity less than 20%
and 12 of them had a prevalence of 30% or more [23]. The
medical care costs of obesity in the United States totalled
about US$147 billion in 2008 [24]. A recent review pro-
vides an overview research on the economic impact of the
obesity epidemic with a broader view of the issue. Besides
the high direct medical costs (obese spent 36-100% more
than normal-weight controls), absenteeism and presentee-
ism were 1,5 times higher, and an increase in disability
payments and disability insurance premiums were shown
[25].
There is widespread agreement across this literature that
the medical costs associated with obesity are substantial;
however, there are important differences between the
studies. Possible factors affecting these differences in esti-
mates of costs are: methodology, categories of costs
included (direct medical costs for diagnosis and treatment,
indirect costs, non medical costs), definitions of weight
categories, age groups, and data sources. These discrepan-
cies make it difficult to compare results in different
settings.
Some limitations on methods used in this study are
worthy of further consideration. Firstly we restricted our
analysis to meta-analysis of prospective studies and case–
control studies carried out in countries other than Brazil,
since no data are available on relative risks based on Bra-
zilian cohorts. So, attributable risks may not reflect the
real burden of the diseases in the country. Thus, our as-
sumption is that the relative risks found in international
studies could be applied to the Brazilian population. Sec-
ondly, in order to interpret PAR as the proportion of cases
that could be prevented if the exposure were eliminated,
we have to consider that confounding factors were con-
trolled when relative risks were estimated. Thirdly, the
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http://www.biomedcentral.com/1471-2458/12/440overweight and obesity prevalence rates obtained from a
Brazilian survey were based on self-reported weight and
height, information that can be easily biased. Lastly,
DATASUS is an administrative database designed with the
purpose of operating the payment for hospitalizations, not
for epidemiological purposes. Many limitations of this
data can be raised as the quality of input data, coverage
(60 to 70%), fraud, duplication of data, among others.
Conclusion
This study provides a comprehensive estimate of the
economic impact of overweight and obesity-related dis-
eases for the Brazilian public health system. The know-
ledge of these costs will be useful for future economic
analysis of preventive and treatment interventions, such
as education programs or new drugs. This may help re-
duce obesity-attributable growth of health care expendi-
tures in Brazil.
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